Core Insights - AbbVie Inc. reported second-quarter 2025 sales of $15.42 billion, exceeding the consensus estimate of $14.98 billion, with a year-over-year sales increase of 6.6% on a reported basis and 6.5% on an operational basis [1] - Adjusted earnings were reported at $2.97, a 12.1% increase year over year, but fell short of the consensus estimate of $3.23 [1] - The company raised its fiscal 2025 adjusted earnings guidance to a range of $11.88-$12.08 per share, compared to the previous range of $11.67-$11.87 and analysts' estimate of $12.24 [1] Sales and Earnings Performance - The sales growth reflects strong performance in key products, particularly Skyrizi and Rinvoq, which are tracking ahead of management's prior long-term targets [3][4] - Guggenheim Partners updated its revenue and EPS estimates for 2025 to $60.69 billion and $12.04, respectively, from previous estimates of $60.02 billion and $11.92 [3] Market Sentiment and Analyst Ratings - Analysts express confidence in AbbVie's outlook for the second half of 2025, despite expectations of some moderation in net pricing [2] - Guggenheim Partners maintains a Buy rating and has increased the price forecast for AbbVie from $216 to $227 [4] - Morgan Stanley has also maintained an Overweight rating and raised the price forecast from $250 to $255 [5] Stock Performance - AbbVie stock is currently trading higher by 3.24% at $195.14 [6]